Cardioprotection--time to take into account clinical complexity: the case of antiplatelet agents : editorial to "two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts" by Xi-Ming Yang et al.
François
F
Roubille
Jean-Claude
JC
Tardif
D000249:Adenosine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D010980:Platelet Membrane Glycoproteins / Q000276:immunology*; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage*
D000906:Antibodies; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D058921:Purinergic P2Y Receptor Antagonists; C098341:platelet membrane glycoprotein VI; D000249:Adenosine Monophosphate; C117446:cangrelor